Western companies are investing in Chinese biotech even amid continued geopolitical tension between China and the West and decreasing appetite for foreign investment in China; Two lithium battery part manufacturers, Capchem and Kedaliplan, plan to build factories in the U.S. to avoid hefty lithium battery tariffs; and Chinese pharma firm Asymchem to take over U.K. Pfizer plant.
Lingang Special Area of the Shanghai FTZ elaborates on the general data of the biomedical, intelligent connected vehicle and public fund sectors
Shanghai specifies record filing procedures for AI services
The release of goods and determination of customs duty amounts may be carried out separately
The People's Court Case Repository is made available to the general public
A branch of a bank may be allowed to sign an insurance agency agreement
Shanghai FTZ expedites cross-border transfer of specified data; CBP investigation finds no substantial evidence of evasion by CIE; and Another Chinese EV SPAC merger is in the pipeline but EU tariffs threaten the business.
Charles Wu of Clyde & Co describes the current regulatory state of China's investment market, for private equity investors, including the much anticipated recent clarity provided by key regulators as well as potential pitfalls to avoid
Shanghai specifies record filing procedures for AI services. The People's Court Case Repository is made available to the general public. A branch of a bank may be allowed to sign an insurance agency agreement.
Procedures are facilitated for marketing of domestically produced foreign pharmaceuticals
